Please assess the completion status of the following clinical trial:

Trial Title: Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Disease Criteria~* Acute leukemia or chronic myelogenous leukemia in blastic crisis or accelerated phase, not in remission at the time of transplant~* Myelodysplastic syndrome, with more than 5% blasts in bone marrow at the time of transplant~* Hodgkin and Non-Hodgkin Lymphomas: Not in CR in PET scan or CT scan before transplant, or relapsed within 1 year from previous remission~* CLL not in remission~* Multiple Myeloma, not in remission~* Suitable donor available (related or unrelated)~Age, Organ Function Criteria~* Age: ≤ 70 years~* Cardiac: LV Ejection Fraction ≥ 40% by MUGA or Echocardiogram~* Pulmonary: FEV1 and FVC ≥ 40% predicted, and DLCO (corrected for hemoglobin) ≥ 40% of predicted~* Renal: Adult population: serum creatinine ≤ 1.0 mg/dL (if serum creatinine \> 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \> 60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation)~* Renal: Pediatric population: serum creatinine clearance ≥ 90 ml/min/1.73 m2 as calculated by the Schwartz formula for estimated GFR~* Hepatic: serum total bilirubin ≤ 2.0 mg/dl and AST / ALT ≤ ULN x 4~* Performance status: Karnofsky ≥ 70%~Exclusion Criteria:~* Other active life-threatening cancer requiring treatment other than allo-HSCT~* HIV1 or HIV2 positive~* Uncontrolled medical or psychiatric disorder~* Uncontrolled viral or fungal infection~* Active CNS leukemia~* Non-compliant to medications~* No appropriate caregivers identified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Clo/BU4 (Type: EXPERIMENTAL): Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).